Ezekiel J. Emanuel, Allen Buchanan, Shuk Ying Chan, Cécile Fabre, Daniel Halliday, Joseph Heath, Lisa Herzog, R. J. Leland, Matthew S. McCoy, Ole F. Norheim, Carla Saenz, G. Owen Schaefer, Kok-Chor Tan, Christopher Heath Wellman, Jonathan Wolff & Govind Persad
Lancet 398 (10304):1015 (2021)
AbstractAll parties involved in researching, developing, manufacturing, and distributing COVID-19 vaccines need guidance on their ethical obligations. We focus on pharmaceutical companies' obligations because their capacities to research, develop, manufacture, and distribute vaccines make them uniquely placed for stemming the pandemic. We argue that an ethical approach to COVID-19 vaccine production and distribution should satisfy four uncontroversial principles: optimising vaccine production, including development, testing, and manufacturing; fair distribution; sustainability; and accountability. All parties' obligations should be coordinated and mutually consistent. For instance, companies should not be obligated to provide host countries with additional booster shots at the expense of fulfilling bilateral contracts with countries in which there are surges. Finally, any satisfactory approach should include mechanisms for assurance that all parties are honouring their obligations. This assurance enables countries, pharmaceutical companies, global organisations, and others to verify compliance with the chosen approach and protect ethically compliant stakeholders from being unfairly exploited by unethical behaviour of others.
Similar books and articles
Who's in the Business of Saving Lives?Pepe Lee Chang - 2006 - Journal of Medicine and Philosophy 31 (5):465-482.
Obligations in a global health emergency - Authors’ reply.Ezekiel Emanuel, Cecile Fabre, Lisa M. Herzog, Ole F. Norheim, Govind Persad, G. Owen Schaefer & Kok-Chor Tan - 2021 - Lancet 398 (10316):2072.
Human Rights Responsibilities of Pharmaceutical Companies in Relation to Access to Medicines.Joo-Young Lee & Paul Hunt - 2012 - Journal of Law, Medicine and Ethics 40 (2):220-233.
Exposing Nursing Students To the Marketing Methods of Pharmaceutical Companies.Murat Civaner, Ozlem Sarikaya, Sevim Ulupinar Alici & Gulcin Bozkurt - 2008 - Nursing Ethics 15 (3):396-410.
Global health impact: A basis for labeling and licensing campaigns?Nicole Hassoun - 2012 - Developing World Bioethics 12 (3):121-134.
Pharmaceutical companies and access to medicines – social integration and ethical CSR resolution of a global public choice problem.Onyeka K. Osuji & Okechukwu Timothy Umahi - 2012 - Journal of Global Ethics 8 (2-3):139-167.
Does the Pharmaceutical Sector Have a Coresponsibility for the Human Right to Health?Doris Schroeder - 2011 - Cambridge Quarterly of Healthcare Ethics 20 (2):298-308.
Urgently Creating the Better in Global Health.Richard Marlink - 2017 - Hastings Center Report 47 (5):25-26.
Standards of Care in Global Health: Identifying the Right Question.Paul Ndebele - 2017 - Hastings Center Report 47 (5):28-29.
Global Health Disparity and Pharmaceutical Companies’ Obligation to Assist.Anita Ho - 2017 - In Dien Ho (ed.), Philosophical Issues in Pharmaceutics: Development, Dispensing, and Use. Springer.
When Law is Not Law: Setting Aside Legal Provisions during Declared Emergencies.Daniel G. Orenstein - 2013 - Journal of Law, Medicine and Ethics 41 (s1):73-76.
Restoring a reputation: invoking the UNESCO Universal Declaration on Bioethics and Human Rights to bear on pharmaceutical pricing.Daniel J. Hurst - 2017 - Medicine, Health Care and Philosophy 20 (1):105-117.
Moral Obligation of Pharmaceutical Companies towards HIV Victims in Developing Countries.Azam Golam - 2008 - The Dhaka University Studies 64 (1):197-212.
Examining Pharmaceutical Exceptionalism: Intellectual Property, Practical Expediency, and Global Health.Govind Persad - 2019 - Yale Journal of Health Policy, Law, and Ethics 18:157-90.
Added to PP
Historical graph of downloads
Citations of this work
No citations found.
References found in this work
No references found.